Evidence map›Paper›PMID 42216106›Full record

ReviewCardio-oncology (London, England)2026

Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement.

Susan Dent, Michelle B Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George and 10 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Susan DentWilmot Cancer Institute, University of Rochester, Rochester, NY, USA. susan_dent@urmc.rochester.edu.ORCID http://orcid.org/0000-0002-9183-9340
Michelle B NadlerPrincess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4372-3204
Anne BlaesUniversity of Minnesota, Minneapolis, USA.ORCID http://orcid.org/0000-0002-5433-4810
Ahamed IqbalTeaching Hospital, Ministry of Health, Batticaloa, SriLanka, Sri Lanka.ORCID http://orcid.org/0000-0003-3506-6088
Hannah Naa Gogwe AyetteyNational Radiotherapy Oncology and Nuclear Medicine Centre, KorleBu Hospital, Accra, Ghana.
Jose Alvarez-CardonaLeon H Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0009-0001-0681-5708
Alexandre ChanDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, USA.ORCID http://orcid.org/0000-0003-4391-4219
Eng-Siew KohDepartment of Radiation Oncology, Liverpool Hospital, Liverpool South Wales, Australia, South West Sydney Clinical School, University of South Wales, Sydney, Australia.ORCID http://orcid.org/0000-0002-1664-2513
Raul Cordoba MascunanoFundacion Jimenez Diaz University Hospital, Madrid, Spain.
Mridula GeorgeRutgers Cancer Institute, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0003-2013-4017
Naa Adorkor AryeeteyNational Radiotherapy Oncology and Nuclear Medicine Centre, KorleBu Hospital, Accra, Ghana.
Erin J HowdenSchool of Health Sciences, University of New South Wales, Sydney, Australia.ORCID http://orcid.org/0000-0002-6657-4395
Sase KazuhiroClinical Pharmacy and Pharmacology an Regulatory Science, Juntendo University, Tokyo, Japan.
Nida LatifSection of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2198-5190
Aya F OzakiDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, USA.ORCID http://orcid.org/0000-0003-0703-9322
Cherith J SempleInstitiute of Nursing and Health Research, Ulster University / Cancer Services, South Eastern Health and Social Care Trust, Belfast, UK.ORCID http://orcid.org/0000-0002-4560-7637
Sivatharshini RamalingamCardio-Oncology Center of Excellence, Royal Brompton Hospital, London, UK.ORCID http://orcid.org/0009-0009-2582-9548
Neil M IyengerWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-9773-5235
Hope S RugoCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-6710-4814
Bogda KoczwaraAustralian Research Centre for Cancer Survivorship, College of Medicine and Public Health, University of New South Wales, Flinders University, Sydney, Adelaide, Australia. b.koczwara@unsw.edu.au.ORCID http://orcid.org/0000-0002-1201-1642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer.

methodsThe International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations.

results5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting systemic CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan.

conclusionsCCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally.

Indexed as

Cancer survivorshipCardiovascular toxicityManagementMultidisciplinary carePrevention

Identifiers

PMID42216106
PMCPMC13220357

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.